Quantification of antigen-reactive T cells by a modified ELISPOT assay based on freshly isolated blood dendritic cells
- PMID: 11835528
- PMCID: PMC6807813
- DOI: 10.1002/jcla.2072
Quantification of antigen-reactive T cells by a modified ELISPOT assay based on freshly isolated blood dendritic cells
Abstract
The enzyme-linked immunospot (ELISPOT) assay has become a widely employed method for quantification of antigen-reactive T lymphocytes. In recent years, various types of antigen-presenting cells (APCs) have been tested as stimulator cells in ELISPOT protocols to achieve a highly sensitive and rapid assay which is not impaired by a marked nonspecific cytokine release. However, the currently available APCs still have disadvantages, such as significant background reactivities, limited sensitivity, and time-consuming preparation procedures. Recently, we succeeded in defining a novel subpopulation of circulating dendritic cells (DCs) that can easily be prepared from human blood. These M-DC8+ DCs proved to be very effective in the induction of antigen-specific T cell responses. In the present study we provide evidence that M-DC8+ DCs are particularly well suited as APCs for the detection of antigen-specific CD8+ T cells after challenge with viral or tumor peptides in ELISPOT assays. In addition, protein-loaded M-DC8+ DCs proved to be quite efficient in the presentation of MHC class II-bound peptides, thus allowing the determination of frequencies of antigen-reactive CD4+ T cells. The use of M-DC8+ DCs as stimulator cells can improve the ELISPOT assay by combining high sensitivity, rapidity, and low background reactivity.
Copyright 2002 Wiley-Liss, Inc.
Similar articles
-
Sequential delivery of maturation stimuli increases human dendritic cell IL-12 production and enhances tumor antigen-specific immunogenicity.J Surg Res. 2004 Jan;116(1):24-31. doi: 10.1016/j.jss.2003.09.003. J Surg Res. 2004. PMID: 14732346
-
Enzyme-linked immunospot, cytokine flow cytometry, and tetramers in the detection of T-cell responses to a dendritic cell-based multipeptide vaccine in patients with melanoma.Clin Cancer Res. 2003 Feb;9(2):641-9. Clin Cancer Res. 2003. PMID: 12576430 Clinical Trial.
-
Paucity of functional T-cell memory to melanoma antigens in healthy donors and melanoma patients.Clin Cancer Res. 2000 Dec;6(12):4831-8. Clin Cancer Res. 2000. PMID: 11156242
-
The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8(+) T lymphocytes in IFN-gamma ELISPOT assays.J Immunol Methods. 2002 Jan 1;259(1-2):95-110. doi: 10.1016/s0022-1759(01)00499-9. J Immunol Methods. 2002. PMID: 11730845
-
Dendritic cell gene therapy.Surg Oncol Clin N Am. 2002 Jul;11(3):645-60. doi: 10.1016/s1055-3207(02)00027-3. Surg Oncol Clin N Am. 2002. PMID: 12487060 Review.
References
-
- Marchand M, Van Baren N, Weynants P, et al. 1999. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLA‐A1. Int J Cancer 80:219–230. - PubMed
-
- Townsend A, Bodmer H. 1989. Antigen recognition by class‐I restricted T lymphocytes. Annu Rev Immunol 7:601–624. - PubMed
-
- Rosenberg SA, Yannelli JR, Yang JC, et al. 1994. Treatment of patients with metastatic melanoma with autologous tumor‐infiltrating lymphocytes and interleukin‐2. J Natl Cancer Inst 86:1159–1166. - PubMed
-
- Pardoll DM, Topalian SL. 1998. The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol 10:588–594. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous